Health Care·Pharmaceuticals·$4.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.20 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.20 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management acknowledged the difficulties faced in the quarter. They emphasized a commitment to long-term strategies without offering specific guidance.
Management did not provide specific updates on revenue expectations.
The company is focusing on strategic initiatives despite the current challenges.
Ligand Pharmaceuticals reported a loss of $0.20 per share, which disappointed investors. The stock reacted negatively, dropping nearly 23%. The lack of revenue figures and guidance contributed to investor uncertainty, leading to the significant decline in stock price.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SYSCO CORP
Nov 7, 2011